---
schema_version: "secwatch.filing_event.v1"
accession: "0001690585-26-000021"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:26:32.238484+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dianthus Q1 net loss $40.8M; cash $1.2B; claseprubart and DNTH212 advance

## Summary
- Net loss $40.8M ($0.85/share) vs $29.5M ($0.82) in Q1 2025; R&D spend $34.5M up from $27.0M.
- Cash $1.2B at March 31, including $719M gross from March public offering; runway into 2030.
- Claseprubart: Early GO in CAPTIVATE CIDP trial; Phase 3 gMG trial mid-2026 with top-line 2H'28.
- DNTH212: Priority indications SjD, SLE, DM; Phase 1 healthy volunteer data expected 2H'26.
- Orphan Drug Designation for claseprubart in MG; FDA agreed to remove ANA screening and DIL reclassification.

## SEC filing metadata
- accession: 0001690585-26-000021
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/0001690585-26-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001690585-26-000021
- JSON: https://secwatch.observer/filing/0001690585-26-000021.json
- Plain text: https://secwatch.observer/filing/0001690585-26-000021.txt

## Key facts
- Earnings Releases
  Dianthus Therapeutics, Inc. /DE/ reported financial results for the first quarter ending March 31, 2026.
  - Period: the first quarter ending March 31, 2026
  - Result: reported results
  source text: On May 5, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/0001690585-26-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.